might get the impression that the pharmaceutical companies really
care about you and your quality of life -- you know, the melancholic
pensive moments, the idyllic walks in the morning dew, the caring
spouse, the playing children, the fawning dog, the comforting but
authoritative voice-over. But sadly, drug companies, like all
corporations, are mandated by law to have no higher goal than making
money for investors. This morning I received the e-mail below. You
might pause and wonder where you fit into this scheme of things.
Vincent
_______________________
Subject: Oncology Market Forecast to 2013
I enclose details of our report on the Oncology Market
How do you uncover the threats and opportunities that your oncology
drug will face this year, next year and each year after that? Our new
report answers your questions with the most comprehensive forecast of
the competitive oncology marketplace ever created. We've pulled
together information over 130 drugs - from today's blockbusters to
tomorrow's most promising breakthrough molecules. Our analysis
provides key decision-making information such as:
- what your competitors are aiming for
- what you need to do to beat them
- what market forces impact your Go/No-Go action
- which indications to target
What do you need to know to make strategic and tactical decisions
about your drug's success?
Our research team analyzed sales performance, legal and regulatory
changes, new product launches and recent changes in research
strategy. We also studied likely trends, critical factors and hidden
pitfalls for the next decade. No other resource gives you so much
bedrock information on which to base your decision-making.
What factors are you already looking at and what else do you need to
be aware of?
Key oncology trends are easy to follow in the headlines. But what's
driving those trends? And what hidden factors are already shifting
your competitors' goals and strategy? This report looks at all the
data to highlight what your team must do to be successful in 2009-
2013 and beyond.
The report contains marketing analysis of over 130 drugs in a dozen
drug classes and adjunct treatments including:
- What's currently approved and what are the upcoming new indications?
- What novel products are in development and what impact
- will they have on the market?
- What are the strategic market growth drivers?
- How are epidemiology and disease information impacting market size?
- What are the U.S. and global outlooks for current and future leaders?
- What are the major market events, such as competitors' new
launches, that your team must be aware of?
- What new research strategies will change the direction of key
companies' pipelines?
With this level of comprehensive analysis, your team doesn't have to
guess when making decisions about how to fund and prioritize products
and franchises. You will have everything you need to make good
decisions today.
For more information please click on:
http://www.researchandmarkets.com/product/92d5c7/oncology_market_forecast_to_2013
Title Index:
Chapter 1: Analysis of Cancer Drugs by Classes (130+ Drug Profiles)
- Antineoplastics (79)
- Alkylating Agents (9)
- Antimetabolites (8)
- Antimitotics (11)
- Cytotoxic Antibiotics (5)
- Hormones (10)
- Tyrosine Kinase Inhibitors (20)
- Monoclonal Antibodies (16)
- Immunostimulants (9)
- Other Cancer Treatments (32)
- Adjunct Treatments (16)
Brand Information
- Brand and generic name
- Drug class
- Delivery mechanism
- Line of treatment
Sales Data
- Historical/current sales
- Forecasted sales
Approved Indications
- Current Product Development Phases
- Competitive and Strategic Positioning
- Market Opportunities and Brand Growth
- Patent, Generic and Litigation Information
Chapter 2: Oncology Indications
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Lung Cancer
- Prostate Cancer
Analysis of Markets for Different Cancer Types
- Current sales, major drugs and important companies
- Forecasted sales and assessment of future drugs and market players
- Pipeline development status
- Major market events, changes in treatments, patent expirations, etc.
Chapter 3: Top Companies' Oncology Portfolios
- Amgen
- AstraZeneca
- BristolMyersSquibb
- Celgene
- Eli Lilly
- GlaxoSmithKline
- ImClone
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Roche
- Sanofi-Aventis
- Schering-Plough
Analysis of Major Oncology Companies
- Current sales, major drugs and important companies
- Forecasted sales and assessment of future drugs and market players
- Pipeline development status
Pricing:
Electronic (PDF) (1 - 5 Users) : EUR 14425
Electronic (PDF) (Enterprisewide) : EUR 28851
Ordering - Three easy ways to place your order:
1] Order online at
http://www.researchandmarkets.com/product/92d5c7/oncology_market_forecast_to_2013
2] Order by fax: Print an Order form from
http://www.researchandmarkets.com/product/92d5c7/oncology_market_forecast_to_2013
and Fax to +353 1 4100 980
3] Order by mail: Print an Order form from
http://www.researchandmarkets.com/product/92d5c7/oncology_market_forecast_to_2013
and post to Research and Markets Ltd. Guinness Center, Taylors Lane,
Dublin 8. Ireland.
------------------------------------
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/cancercured/
<*> Your email settings:
Individual Email | Traditional
<*> To change settings online go to:
http://groups.yahoo.com/group/cancercured/join
(Yahoo! ID required)
<*> To change settings via email:
mailto:cancercured-digest@yahoogroups.com
mailto:cancercured-fullfeatured@yahoogroups.com
<*> To unsubscribe from this group, send an email to:
cancercured-unsubscribe@yahoogroups.com
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
Tidak ada komentar:
Posting Komentar